Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
Buy
53
AZN Quote, Financials, Valuation and Earnings
Last price:
$67.30
Seasonality move
:
4.45%
Day range:
$69.84 - $70.69
52-week range:
$61.24 - $87.68
Dividend yield:
2.21%
P/E ratio:
28.14x
P/S ratio:
3.98x
P/B ratio:
5.29x
Volume:
4M
Avg. volume:
6.3M
1-year change:
-8.19%
Market cap:
$217.2B
Revenue:
$54.1B
EPS (TTM):
$2.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$13.7B | $1.12 | 8.72% | 84.16% | $84.16 |
|
AMGN
Amgen
|
$8B | $4.26 | 5.5% | 281.73% | $315.35 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
BNTX
BioNTech SE
|
$183.4M | -$2.66 | 11.73% | -20.7% | $136.23 |
|
GSK
GSK PLC
|
$10B | $1.04 | 5.98% | 60.08% | $41.59 |
|
MRNA
Moderna
|
$115.3M | -$3.11 | -49.84% | -11.55% | $46.96 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$70.07 | $84.16 | $217.2B | 28.14x | $1.05 | 2.21% | 3.98x |
|
AMGN
Amgen
|
$275.84 | $315.35 | $148.3B | 25.17x | $2.38 | 3.31% | 4.37x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.38 | $17.94 | $3.5M | -- | $0.00 | 0% | 1.44x |
|
BNTX
BioNTech SE
|
$92.80 | $136.23 | $22.3B | 191.55x | $0.00 | 0% | 7.52x |
|
GSK
GSK PLC
|
$37.17 | $41.59 | $75.5B | 19.27x | $0.40 | 4.18% | 1.91x |
|
MRNA
Moderna
|
$24.06 | $46.96 | $9.3B | -- | $0.00 | 0% | 2.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
42.02% | 0.321 | 13.05% | 0.69x |
|
AMGN
Amgen
|
90.24% | 0.239 | 34.26% | 0.74x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.357 | -- | 1.20x |
|
BNTX
BioNTech SE
|
1.53% | 1.910 | 1.45% | 9.86x |
|
GSK
GSK PLC
|
56.56% | -0.257 | 30.39% | 0.58x |
|
MRNA
Moderna
|
-- | 0.406 | -- | 3.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$11.3B | $3.7B | 10.93% | 19.55% | 27.61% | $2.7B |
|
AMGN
Amgen
|
$5.2B | $1.2B | 8.85% | 97.08% | 33.08% | $980M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
BNTX
BioNTech SE
|
$104.2M | -$562M | -3.86% | -3.91% | -225.11% | -$1.5B |
|
GSK
GSK PLC
|
$7B | $2.8B | 10.19% | 23.08% | 30.2% | $877.6M |
|
MRNA
Moderna
|
$17M | -$1.1B | -29.23% | -29.23% | -900% | -$1.2B |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 21.23%. AstraZeneca PLC's return on equity of 19.55% beat Amgen's return on equity of 97.08%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B AMGNAmgen63.58% $3.20 $63.6B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $84.16, signalling upside risk potential of 20.11%. On the other hand Amgen has an analysts' consensus of $315.35 which suggests that it could grow by 14.32%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 AMGNAmgen9 14 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.396, which suggesting that the stock is 60.428% less volatile than S&P 500. In comparison Amgen has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.829%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.21%. Amgen offers a yield of 3.31% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Amgen quarterly revenues of $8.1B. AstraZeneca PLC's net income of $2.9B is higher than Amgen's net income of $1.7B. Notably, AstraZeneca PLC's price-to-earnings ratio is 28.14x while Amgen's PE ratio is 25.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.98x versus 4.37x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.98x 28.14x $13.6B $2.9B AMGNAmgen4.37x 25.17x $8.1B $1.7B
-
Which has Higher Returns AZN or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of 21.46% compared to AstraZeneca PLC's net margin of --. AstraZeneca PLC's return on equity of 19.55% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About AZN or BDRX?
AstraZeneca PLC has a consensus price target of $84.16, signalling upside risk potential of 20.11%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1200.28%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than AstraZeneca PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is AZN or BDRX More Risky?
AstraZeneca PLC has a beta of 0.396, which suggesting that the stock is 60.428% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.
-
Which is a Better Dividend Stock AZN or BDRX?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.21%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or BDRX?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. AstraZeneca PLC's net income of $2.9B is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, AstraZeneca PLC's price-to-earnings ratio is 28.14x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.98x versus 1.44x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.98x 28.14x $13.6B $2.9B BDRXBiodexa Pharmaceuticals PLC1.44x -- -- --
-
Which has Higher Returns AZN or BNTX?
BioNTech SE has a net margin of 21.46% compared to AstraZeneca PLC's net margin of -227.46%. AstraZeneca PLC's return on equity of 19.55% beat BioNTech SE's return on equity of -3.91%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B BNTXBioNTech SE54.16% -$1.82 $20.8B -
What do Analysts Say About AZN or BNTX?
AstraZeneca PLC has a consensus price target of $84.16, signalling upside risk potential of 20.11%. On the other hand BioNTech SE has an analysts' consensus of $136.23 which suggests that it could grow by 46.8%. Given that BioNTech SE has higher upside potential than AstraZeneca PLC, analysts believe BioNTech SE is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 BNTXBioNTech SE13 4 0 -
Is AZN or BNTX More Risky?
AstraZeneca PLC has a beta of 0.396, which suggesting that the stock is 60.428% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.347, suggesting its more volatile than the S&P 500 by 34.675%.
-
Which is a Better Dividend Stock AZN or BNTX?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.21%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or BNTX?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than BioNTech SE quarterly revenues of $192.3M. AstraZeneca PLC's net income of $2.9B is higher than BioNTech SE's net income of -$437.5M. Notably, AstraZeneca PLC's price-to-earnings ratio is 28.14x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.98x versus 7.52x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.98x 28.14x $13.6B $2.9B BNTXBioNTech SE7.52x 191.55x $192.3M -$437.5M
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 21.61%. AstraZeneca PLC's return on equity of 19.55% beat GSK PLC's return on equity of 23.08%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B GSKGSK PLC74.23% $0.99 $41.5B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $84.16, signalling upside risk potential of 20.11%. On the other hand GSK PLC has an analysts' consensus of $41.59 which suggests that it could grow by 11.9%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 GSKGSK PLC2 4 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.396, which suggesting that the stock is 60.428% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.539, suggesting its less volatile than the S&P 500 by 46.147%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.21%. GSK PLC offers a yield of 4.18% to investors and pays a quarterly dividend of $0.40 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $9.5B. AstraZeneca PLC's net income of $2.9B is higher than GSK PLC's net income of $2B. Notably, AstraZeneca PLC's price-to-earnings ratio is 28.14x while GSK PLC's PE ratio is 19.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.98x versus 1.91x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.98x 28.14x $13.6B $2.9B GSKGSK PLC1.91x 19.27x $9.5B $2B
-
Which has Higher Returns AZN or MRNA?
Moderna has a net margin of 21.46% compared to AstraZeneca PLC's net margin of -907.48%. AstraZeneca PLC's return on equity of 19.55% beat Moderna's return on equity of -29.23%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B MRNAModerna15.89% -$2.52 $10.1B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of $84.16, signalling upside risk potential of 20.11%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 95.19%. Given that Moderna has higher upside potential than AstraZeneca PLC, analysts believe Moderna is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 MRNAModerna5 17 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.396, which suggesting that the stock is 60.428% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.21%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Moderna quarterly revenues of $107M. AstraZeneca PLC's net income of $2.9B is higher than Moderna's net income of -$971M. Notably, AstraZeneca PLC's price-to-earnings ratio is 28.14x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.98x versus 2.98x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.98x 28.14x $13.6B $2.9B MRNAModerna2.98x -- $107M -$971M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
